Answers are grounded in this paper and cite their sources.
Upregulation of soluble or membrane bound receptor activator of nuclear factor kappa B ligand (RANKL) in the multiple myeloma (MM) microenvironment is pivotal for the pathological activation of osteoclasts and development of myeloma bone disease. 1 This process largely depends on the ability of malignant plasma cells to provoke apoptosis of osteocytes. 2 Highlighting the importance of RANKL in the biology of MM, it was previously shown that the RANKL to osteoprotegerin (a RANKL decoy receptor) ratio predicts survival. 3 RANKL is also induced on the surface of CD4 + T cells by IL-7 (ref. 4 ) and CD4 + Th17 T cells with pro-osteoclastogenic activity are increased in the peripheral blood (PB) and bone marrow (BM) of patients with myeloma. 5 , 6
No takes yet. Share an insight, caveat, or question.
Spanoudakis et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: